Rufinamide 15N,D2
| Product Name | Rufinamide 15N,D2 |
|---|---|
| Alternate Names | Rufinamide Stable Isotopes, Stable Isotopes of Rufinamide |
| CAT No. | CS-O-02951 |
| CAS No. | 1795037-48-7 |
| Category | Stable Isotopes |
| Stock | IN-Stock |
| Mol. Wt. | 241.20 g/mol |
| Mol. For. | C₁₀H₆D₂F₂N₃¹⁵NO |
| Hazardous | This is a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Rufinamide |
| Purity | Not less than 95 % |
| Therapeutic | Anticonvulsants (Anti-Epileptics) |
| Smileys | FC1=C(C(F)=CC=C1)C([2H])([2H])N2C=C(C([15NH2])=O)N=N2 |
| Canonical Smiles | C1=CC(=C(C(=C1)F)CN2C=C(N=N2)C(=O)N)F |
| InchIKey | POGQSBRIGCQNEG-RPVANBMVSA-N |
| Inchl | InChI=1S/C10H8F2N4O/c11-7-2-1-3-8(12)6(7)4-16-5-9(10(13)17)14-15-16/h1-3,5H,4H2,(H2,13,17)/i4D2,13+1 |
| IUPAC | 1-[dideuterio-(2,6-difluorophenyl)methyl]triazole-4-(15N)carboxamide |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Rufinamide is an antiepileptic medication that is used to treat seizures in patients with Lennox-Gastaut syndrome, a rare form of epilepsy. It works by reducing the abnormal electrical activity in the brain that causes seizures. Rufinamide 15N D2 is a stable isotope-labeled form of the drug, which is used in pharmacokinetic and pharmacodynamic studies to determine how the drug is metabolized and how it interacts with the body.
The chemical formula of Rufinamide 15N D2 is C10H7D2N3O, and its molecular weight is 190.22 g/mol. The drug is classified as a triazole derivative and has a half-life of approximately 6-10 hours. It is primarily metabolized by the liver and excreted in the urine.
Rufinamide 15N D2 is typically administered orally in tablet form, with dosages ranging from 200 mg to 1600 mg per day. It is important to follow the prescribed dosage and schedule to achieve the best results and avoid potential side effects.
Common side effects of Rufinamide include dizziness, fatigue, nausea, vomiting, and tremors. More serious side effects may include suicidal thoughts, depression, and allergic reactions. Patients should consult with their healthcare provider if they experience any side effects or have concerns about the medication.
Overall, Rufinamide 15N D2 is an important tool in the study of antiepileptic drugs and the treatment of Lennox-Gastaut syndrome. Its stable isotope-labeled form allows for more precise analysis of the drug's effects on the body, which can ultimately lead to better treatment options for patients.
Get an Instant Quote
Related Compounds
Rufinamide D2 metabolite |